ClinicaliQ Trial Snapshot
- Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders — Recruiting • Phase II • NCT07104565.
- Tafasitamab was tested in adults with autoimmune blood disorders to assess whether it was safe and effective.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders. Conditions: Immune Thrombocytopenia Interventions: INCA000585 Lead Sponsor: Incyte Corporation Planned Enrollment: 56 participants